These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1175127)

  • 1. Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization.
    de Gast GC; The TH; Schraffordt Koops H; Huiges HA; Oldhoff J; Nieweg HO
    Cancer; 1975 Oct; 36(4):1289-97. PubMed ID: 1175127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary immune response to Helix pomatia haemocyanin in malignant melanoma. Relationship between 19S and 7S antibody response and in vitro lymphocyte transformation.
    Gast GC; The TH; Schraffordt Koops H; Snijder AM; Huiges HA
    Clin Exp Immunol; 1976 Mar; 23(3):491-8. PubMed ID: 947647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.
    Bulkley GB; Cohen MH; Banks PM; Char DH; Ketcham AS
    Cancer; 1975 Aug; 36(2):485-94. PubMed ID: 1157014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of lymphocyte responses to phytohemagglutinin in melanoma patients. (lack o prognostic value of correlation with minimal tumor burden).
    Kovarík J; Ninger E; Zemanová D; Lauerová L
    Neoplasma; 1980; 27(5):575-82. PubMed ID: 7231613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro lymphocyte reactivity and T cell levels in patients with melanoma: correlations with clinical and pathological stage.
    Silverman NA; Alexander JC; Potvin C; Chretien PB
    Surgery; 1976 Mar; 79(3):332-9. PubMed ID: 1083075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between lymphocyte response to tetanus toxoid and age of lymphocyte donor.
    Peel MM; Edsall G; White WG; Barnes GM
    J Hyg (Lond); 1978 Apr; 80(2):259-65. PubMed ID: 632566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immune competence of patients with Crohn's disease (author's transl)].
    Tönnesmann E; Bürkle PA; Schäfer B; Federlin K
    Klin Wochenschr; 1979 Oct; 57(20):1097-107. PubMed ID: 513603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
    Serov AA; Kadagidze ZG
    Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
    Rangel DM; Golub SH; Morton DL
    Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease.
    Pritchard DJ; Ritts RE; Taylor WF; Miller GC
    Cancer; 1978 Jun; 41(6):2165-73. PubMed ID: 306870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro lymphocyte reactivity to soluble tumor extracts in Sinclair melanoma swine.
    Aultman MD; Hook RR
    Int J Cancer; 1979 Nov; 24(5):673-8. PubMed ID: 528082
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro and in vivo immune response to specific antigens in canine marrow graft recipients.
    Abb J; Kolb HJ; Rodt HV; Grosse-Wilde H; Rieder I; Thierfelder S
    Z Immunitatsforsch Immunobiol; 1977 Jul; 153(2):152-61. PubMed ID: 71795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential evaluation of immunoreactivity in patients with melanoma undergoing surgery and adjuvant therapy.
    Dionigi R; Dominioni L; Gnes F; Bonera A; Prati U; Scarponi A; Robustelli Della Cuna G; Pavesi L; Campani M
    Tumori; 1980 Feb; 66(1):59-76. PubMed ID: 6966434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte-mediated cytotoxicity on human tumor cells in vitro.
    Schwenke H; Schönfelder M
    Arch Geschwulstforsch; 1975; 45(8):802-9. PubMed ID: 1241765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF; Shingleton WW; Pickrell KL
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phytohemagglutinin skin tests in cancer patients.
    Zuckerman KS; LoBuglio AF
    Cancer; 1977 Jun; 39(6):2355-61. PubMed ID: 266970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
    Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
    J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunodiagnostics of malignant disease. VI. Electrophoretic mobility test (EMT) in malignant melanoma.
    Douwes FR; Spellmann HJ; Mross K; Wolfrum DI
    Oncology; 1978; 35(4):163-7. PubMed ID: 81476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.